Skip to content
Inciteful Med

The Diagnostic Process & Criteria

Last updated:

ALS is diagnosed through a process of exclusion, combining clinical exams, MRI scans, and blood panels to rule out other conditions. The gold standard test is the EMG to detect nerve damage, while newer tools like the Gold Coast Criteria and NfL blood tests help confirm the diagnosis earlier.

Key Takeaways

  • • ALS is a diagnosis of exclusion that requires ruling out other conditions through MRIs, blood panels, and clinical exams.
  • • The Gold Coast Criteria provides a simplified 'yes or no' approach, allowing for an earlier ALS diagnosis than older criteria.
  • • Electromyography (EMG) is the gold standard test, capable of detecting hidden lower motor neuron damage in muscles that still feel strong.
  • • The Serum Neurofilament Light (NfL) blood test measures a protein released during nerve damage, helping doctors track disease progression.
  • • Genetic testing for mutations like C9orf72 or SOD1 is highly recommended to determine eligibility for targeted therapies and clinical trials.

The process of diagnosing ALS is often described as a “diagnosis of exclusion.” Because there is no single blood test or scan that can say “yes” or “no” with 100% certainty, doctors must combine your clinical symptoms, electrical tests of your muscles, and advanced imaging to build a complete picture while ruling out other possibilities [1][2].

The Evolution of Diagnostic Criteria

For decades, doctors used complex systems to determine how “certain” an ALS diagnosis was. You may hear these terms in your appointments:

  • Revised El Escorial & Awaji Criteria: These older systems used categories like “possible,” “probable,” or “definite” ALS [3][4]. While they were very accurate, they were often criticized for being too complex and sometimes delaying a diagnosis until the disease had progressed significantly [5][6].
  • Gold Coast Criteria (GCC): Introduced more recently, these criteria are much simpler. Instead of multiple categories of “certainty,” they use a “yes or no” approach [3]. The Gold Coast Criteria allow for an earlier diagnosis by focusing on evidence of progressive weakness and damage to both types of motor neurons, which helps patients access clinical trials and treatments sooner [7][8].

The “Gold Standard” Test: Electromyography (EMG)

The Electromyography (EMG) is the most critical tool for confirming ALS. During this test, a small needle is inserted into various muscles to record their electrical activity [9].

  • Detecting “Hidden” Damage: The EMG can find evidence of lower motor neuron damage in muscles that still feel perfectly strong to you [9][10].
  • Active Denervation: Doctors look for specific patterns, such as “fibrillations” or “positive sharp waves,” which indicate that a muscle has lost its connection to its nerve and is “misfiring” [11][10].
  • Ruling Out Mimics: A related test, the Nerve Conduction Study (NCS), checks how fast signals travel through your nerves. In ALS, these signals usually travel at a normal speed, which helps rule out other conditions like Multifocal Motor Neuropathy (MMN) [10][12].

The Emerging Role of Biomarkers

While the diagnosis is still primarily clinical, a new blood test is changing how doctors understand the disease: Serum Neurofilament Light (NfL).

  • What it is: NfL is a structural protein found inside nerve cells. When those cells are damaged or die, the protein “leaks” into the blood [13][14].
  • Why it matters: High levels of NfL are a strong indicator of active nerve damage [15]. While it isn’t used to diagnose ALS on its own yet, a baseline NfL level can help your doctor understand how aggressive the disease might be and monitor how well you are responding to new therapies [16][17][18].

Completeness Checklist: Your Diagnostic Workup

A thorough diagnostic process should include most, if not all, of the following steps to ensure accuracy [19][12][20]:

  1. Clinical Neurological Exam: Checking reflexes, muscle strength, and muscle tone across multiple body regions (arms, legs, and bulbar muscles).
  2. EMG/NCS: Testing multiple muscles in at least three different body regions.
  3. MRI (Brain and/or Spine): To rule out structural issues like a pinched nerve or a tumor.
  4. Blood Panels: To rule out metabolic, inflammatory, or autoimmune conditions (e.g., Vitamin B12 deficiency, thyroid issues, or specific antibodies).
  5. Genetic Testing: To check for mutations in genes like C9orf72 or SOD1, which is heavily recommended for all patients as it can open the door to targeted therapies [21][22].

Frequently Asked Questions

What tests are used to diagnose ALS?
ALS is diagnosed using a combination of a clinical neurological exam, Electromyography (EMG), Nerve Conduction Studies (NCS), MRIs, and blood panels. Because there is no single test for ALS, doctors must thoroughly rule out other conditions that can mimic the disease.
What is the Gold Coast Criteria for ALS?
The Gold Coast Criteria is a modern, simplified system used by doctors to diagnose ALS. Instead of older categories like 'possible' or 'probable' ALS, it uses a straightforward 'yes or no' approach that helps patients get diagnosed and access treatments earlier.
Why is an EMG necessary for an ALS diagnosis?
An Electromyography (EMG) is the gold standard test for ALS because it can detect hidden nerve damage in muscles that still feel strong to you. It looks for specific electrical misfires, such as fibrillations, that indicate a muscle has lost its connection to the nerve.
What is the NfL blood test for ALS?
Serum Neurofilament Light (NfL) is a structural protein that leaks into the blood when nerve cells are damaged. While not used to diagnose ALS on its own, testing your NfL levels helps doctors understand disease progression and monitor how well you respond to therapies.
Should I get genetic testing if I am being evaluated for ALS?
Yes, genetic testing is heavily recommended during an ALS diagnostic workup. Identifying specific genetic mutations, such as C9orf72 or SOD1, can open the door to targeted therapies and clinical trials.

Questions for Your Doctor

  • • Which specific diagnostic criteria (Gold Coast, Awaji, or Revised El Escorial) were used to confirm my diagnosis?
  • • Did my EMG show 'subclinical' damage in muscles that still feel strong to me?
  • • Can we test my serum neurofilament light (NfL) levels to help establish a baseline for my progression?
  • • What other conditions were ruled out during my workup, and what tests (like MRI or blood panels) were used to do so?
  • • Do my test results make me a candidate for any current clinical trials?

Questions for You

  • • Have I noticed muscle twitching (fasciculations) in areas where I don't yet feel weak?
  • • Did my doctor perform a thorough physical exam that included checking my reflexes and muscle tone in my arms, legs, and jaw?
  • • Am I comfortable with the explanation of why other potential causes for my symptoms have been ruled out?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Diagnosis Particularities of Amyotrophic Lateral Sclerosis in an Elderly Patient.

    Marcu IR, Patru S, Bighea AC

    Current health sciences journal 2018; (44(1)):92-96 doi:10.12865/CHSJ.44.01.16.

    PMID: 30622763
  2. 2

    Is the ALS a motor neuron disease or a hematopoietic stem cell disease?

    Bryukhovetskiy AS, Grivtsova LY, Sharma HS

    Progress in brain research 2020; (258()):381-396 doi:10.1016/bs.pbr.2020.09.005.

    PMID: 33223039
  3. 3

    Diagnostic criteria for amyotrophic lateral sclerosis.

    Timmins HC, Thompson AE, Kiernan MC

    Current opinion in neurology 2024; (37(5)):570-576 doi:10.1097/WCO.0000000000001302.

    PMID: 39037015
  4. 4

    Diagnostic criteria for amyotrophic lateral sclerosis: A multicentre study of inter-rater variation and sensitivity.

    Johnsen B, Pugdahl K, Fuglsang-Frederiksen A, et al.

    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2019; (130(2)):307-314 doi:10.1016/j.clinph.2018.11.021.

    PMID: 30573424
  5. 5

    Management of amyotrophic lateral sclerosis in clinical practice: Results of the expert consensus using the Delphi methodology.

    Cassereau J, Bernard E, Genestet S, et al.

    Revue neurologique 2023; (179(10)):1134-1144 doi:10.1016/j.neurol.2023.07.011.

    PMID: 37827930
  6. 6

    Gold Coast criteria expand clinical trial eligibility in amyotrophic lateral sclerosis.

    Jewett G, Khayambashi S, Frost GS, et al.

    Muscle & nerve 2022; (66(4)):397-403 doi:10.1002/mus.27660.

    PMID: 35673968
  7. 7

    The Gold Coast criteria increases the diagnostic sensitivity for amyotrophic lateral sclerosis in a Chinese population.

    Shen D, Yang X, Wang Y, et al.

    Translational neurodegeneration 2021; (10(1)):28 doi:10.1186/s40035-021-00253-2.

    PMID: 34372918
  8. 8

    [Gold Coast Criteria: A New Diagnostic Paradigm in the Era of Disease-Modifying Therapy for Amyotrophic Lateral Sclerosis].

    Yamakawa I, Urushitani M

    Brain and nerve = Shinkei kenkyu no shinpo 2024; (76(11)):1217-1223 doi:10.11477/mf.1416202763.

    PMID: 39523614
  9. 9

    Electrodiagnosis of Amyotrophic Lateral Sclerosis: A Review of Existing Guidelines.

    de Carvalho M

    Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society 2020; (37(4)):294-298 doi:10.1097/WNP.0000000000000682.

    PMID: 33151660
  10. 10

    Awaji criteria for the diagnosis of amyotrophic lateral sclerosis in Hanoi, Vietnam.

    Van Nguyen T, Tran TA, Vu HT

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2022; (43(1)):393-398 doi:10.1007/s10072-021-05333-9.

    PMID: 34023955
  11. 11

    Lower motor neuron dysfunction in ALS.

    de Carvalho M, Swash M

    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2016; (127(7)):2670-81.

    PMID: 27117334
  12. 12

    Amyotrophic lateral sclerosis or not: Keys for the diagnosis.

    Lenglet T, Camdessanché JP

    Revue neurologique 2017; (173(5)):280-287 doi:10.1016/j.neurol.2017.04.003.

    PMID: 28461025
  13. 13

    Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis.

    Gille B, De Schaepdryver M, Goossens J, et al.

    Neuropathology and applied neurobiology 2019; (45(3)):291-304 doi:10.1111/nan.12511.

    PMID: 29908069
  14. 14

    Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis.

    Abu-Rumeileh S, Vacchiano V, Zenesini C, et al.

    Journal of neurology 2020; (267(6)):1699-1708 doi:10.1007/s00415-020-09761-z.

    PMID: 32100123
  15. 15

    Serum neurofilament light chain cut-off definition for clinical diagnosis and prognosis of amyotrophic lateral sclerosis.

    Brousse M, Delaby C, De La Cruz E, et al.

    European journal of neurology 2023; (30(7)):1919-1927 doi:10.1111/ene.15813.

    PMID: 37029777
  16. 16

    Neurofilament markers in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

    Shi J, Qin X, Chang X, et al.

    Journal of cellular and molecular medicine 2022; (26(2)):583-587 doi:10.1111/jcmm.17100.

    PMID: 34866307
  17. 17

    Correlations of cerebrospinal fluid neurofilament light chain levels with clinical and electromyography findings in amyotrophic lateral sclerosis.

    Matur Z, Deveci Ş, Erdal Y

    Irish journal of medical science 2025; doi:10.1007/s11845-025-04209-7.

    PMID: 41364409
  18. 18

    Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapies.

    A Virata MC, Catahay JA, Lippi G, Henry BM

    Neurodegenerative disease management 2024; (14(6)):227-239 doi:10.1080/17582024.2024.2421738.

    PMID: 39545606
  19. 19

    Split phenomena in amyotrophic lateral sclerosis: Current evidences, pathogenetic hypotheses and diagnostic implications.

    Zoccolella S, Giugno A, Logroscino G

    Frontiers in neuroscience 2022; (16()):1100040 doi:10.3389/fnins.2022.1100040.

    PMID: 36699516
  20. 20

    Motor Neuron Disease in a Patient With Cervical Spondylotic Myelopathy: Too Much Bad Luck.

    Robles LA, Chakravarthy V

    Cureus 2021; (13(1)):e12523 doi:10.7759/cureus.12523.

    PMID: 33564527
  21. 21

    Emerging role of microRNAs in the pathogenesis of amyotrophic lateral sclerosis.

    Akbari Dilmaghani N, Hussen BM, Nateghinia S, et al.

    Metabolic brain disease 2021; (36(5)):737-749 doi:10.1007/s11011-021-00697-5.

    PMID: 33604874
  22. 22

    Atypical Familial Amyotrophic Lateral Sclerosis Secondary to Superoxide Dismutase 1 Gene Mutation With Coexistent Axonal Polyneuropathy: A Challenging Diagnosis.

    Makkawi S, Alqarni AA, Alghaythee H, et al.

    Cureus 2022; (14(1)):e20989 doi:10.7759/cureus.20989.

    PMID: 35154965

This page is for informational purposes only and does not replace professional medical advice. Always consult your neurologist to understand your specific diagnostic test results and care plan.

Stay up to date

Get notified when new research about Amyotrophic lateral sclerosis is published.

No spam. Unsubscribe anytime.